Bayer buys Algeta
Bayer is ponying up $2.9 billion to buy now-former oncology partner Algeta, reports PMLive. The deal means Bayer will own the prostate cancer therapy Xofigo outright.
The company previously estimated the alpha-particle-emitting therapeutic agent would hit $1.3 billion in annual sales.
The FDA approved the treatment in May.